Long term responders in frontline multiple myeloma—exception vs expectation of the modern era #mmsm #myeloma | Huntsman Cancer Institute Blood Cancer Journal nature.com/articles/s4140…

Risk-adapted treatment in multiple myeloma: Does more make it merrier? #mmsm #myeloma | Gliceida Galarza, MD onlinelibrary.wiley.com/doi/10.1111/bj…

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience #mmsm #myeloma | CharlotteBWagner Huntsman Cancer Institute

Congratulations Dr. Sborov! #mmsm | Huntsman Cancer Institute

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma #mmsm #myeloma | Manni Mohyuddin Kelley Louise Julian, PharmD, BCOP Huntsman Cancer Institute Blood Cancer Journal nature.com/articles/s4140…

Ruth Hill felt lost after her multiple myeloma diagnosis, but palliative care helped her regain control and find hope again. bit.ly/3YT58Lo Huntsman Myeloma UofUPalliativeCare

Comparison of patients with myeloma receiving zoledronic acid versus denosumab: A nationwide retrospective cohort study #mmsm #myeloma | Manni Mohyuddin Huntsman Cancer Institute Blood Advances ashpublications.org/bloodadvances/…

New paper in The Oncologist exploring whether smoldering myeloma is more responsive or curable than myeloma. #mmsm Manni Mohyuddin Hira Mian Raj Chakraborty Samer Al Hadidi, MD,MS,FACP pubmed.ncbi.nlm.nih.gov/39236068/

This article reviews clinical trials of smoldering multiple myeloma, comparing efficacy of treatment regimens in smoldering multiple myeloma to results from these regimens when used in newly diagnosed multiple myeloma. doi.org/10.1093/oncolo… #myeloma #BloodCancerAwareness

Be sure to register for the upcoming Park City Myeloma and Lymphoma Summit! See link below for details⬇️ #mmsm #myeloma #Lymphoma | Huntsman Cancer Institute Beyond Trauma Foundation education.binayfoundation.org/content/park-c…

Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria #mmsm #myeloma | Manni Mohyuddin Huntsman Cancer Institute pubmed.ncbi.nlm.nih.gov/39314111/

Be sure to read the recently released article: Should we screen for plasma cell dyscrasias in people with low bone density? #mmsm #myeloma | Manni Mohyuddin Huntsman Cancer Institute The Lancet Haematology

Transplant in myeloma: individualized approaches needed depending on context, access and biology #mmsm #myeloma | Manni Mohyuddin Huntsman Cancer Institute nature.com/articles/s4140…

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma #mmsm #myeloma | Gliceida Galarza, MD Huntsman Cancer Institute Blood Cancer Journal nature.com/articles/s4140…

Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study #mmsm #myeloma | Manni Mohyuddin Huntsman Cancer Institute nature.com/articles/s4140…

First author Gliceida Galarza, MD is one of our amazingly talented Utah Hematology/Oncology Fellows fellows Huntsman Cancer Institute Awesome work Gli! 💫💫💫 Blood Cancer Journal #mmsm

The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization? #mmsm #myeloma | Manni Mohyuddin Huntsman Cancer Institute tandfonline.com/eprint/XY4SVPP…

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Careful Patient Selection and Toxicity Monitoring @MyelomaSLC Huntsman Cancer Institute #mmsm onclive.com/view/car-t-cel…

Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis #mmsm #myeloma | Manni Mohyuddin Huntsman Cancer Institute pubmed.ncbi.nlm.nih.gov/39348665/

The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma Manni Mohyuddin #mmsm academic.oup.com/oncolo/advance…